# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `full27_study-forensics-032_Claude_Sonnet_2e7678`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:06:41.708197+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Sonnet
**Winner:** Claude Sonnet — **37.0/100** (margin: 0.0)
**Failure modes:** missed_key_insight, unsupported_conclusion, unused_assumption, wrong_answer
**Forensic flags:** 2
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Sonnet | 0.0/30 | 0.0/8 | 4.8/8 | 3.4/6 | 3.9/6 | 4.5/6 | 2.4/8 | 8.0/8 | 0.0/10 | 10.0/10 | **37.0/100** |

## Study Forensics Audit

### Claude Sonnet

**Classification:** `mechanism_vs_evidence` [x] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization

## Reasoning Integrity Audit

### Claude Sonnet
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 5

## Mechanism Analysis

### Claude Sonnet
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Sonnet
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Sonnet

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"


## Evidence Map

### Claude Sonnet

**Correctness:** 0.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: No match (got: mechanism_vs_evidence)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 5
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[1]`: "Identified conclusion tier: company claims about cardiovascular protection, transforming outcomes for heart attack/strok"
    _Most informative reasoning step_
  - Note: 5 reasoning steps
  - Note: Low step utility: 0/5 steps contribute

**Assumption Discipline:** 3.4/6
  - (+) `assumptions[2]`: "The company is making claims about cardiovascular protection and heart attack/stroke prevention"
    _Most substantive assumption_
  - (-) `assumptions[3]`: "This is familial hypercholesterolemia patients on maximum statin therapy"
    _Declared but unused in reasoning_
  - Note: 4/4 substantive assumptions
  - Note: 1 unused assumption(s)

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[2]`: "Whether familial hypercholesterolemia context changes the evidence standard"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.9"
    _Stated confidence level_
  - Note: 3 uncertainties (3 substantive)
  - Note: Confidence 0.9

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[0]`: "Could be overclaim due to strong language like 'major breakthrough' and 'transform outcomes'"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 genuinely diverse alternatives

**Self Monitoring Quality:** 2.4/8
  - (+) `self_check[3]`: "Considered whether this could be solid - but the therapeutic benefit claims exceed the biomarker evidence"
    _Most substantive self-verification step_
  - (-) `self_check[1]`: "Verified no cardiovascular events were measured"
    _Fluff self-check_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 2 arithmetic, 2 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.78, 234 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "ed bridge: ldl reduction is a surrogate endpoint, not a direct measure of card"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Sonnet

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'overclaim'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'overclaim', detected 'mechanism_vs_evidence'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Unused Assumption** `[HEURISTIC]`: Assumption 'This is familial hypercholesterolemia patients on maximum st...' is declared but not referenced in reasoning
  - `assumptions[3]`: "This is familial hypercholesterolemia patients on maximum statin therapy"
  - _Impacts: assumption_discipline_


## Consistency & Grounding Audit

### Claude Sonnet

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/12 content words)
  - `key_claims[0]`: "Company claims cardiovascular protection and improved heart attack/stroke outcomes based solely on L"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/7 content words)
  - `key_claims[2]`: "Accelerated approval sought based on surrogate endpoint alone"
- **[WARN]** `[HEURISTIC]` `unused_assumption`: Assumption 4 appears unused in reasoning or answer
  - `assumptions[3]`: "This is familial hypercholesterolemia patients on maximum statin therapy"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "Could be overclaim due to strong language like 'major breakthrough' and 'transform outcomes'"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "Could be solid if focusing only on the LDL reduction finding itself"


## Agent Profiles

### Claude Sonnet (claude-sonnet-4-20250514)
**Parse OK:** True | **Latency:** 11163ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.9

**Assumptions:**
- The Phase 2 trial only measured LDL cholesterol reduction and liver safety
- No cardiovascular outcomes were measured in this 12-week trial
- The company is making claims about cardiovascular protection and heart attack/stroke prevention
- This is familial hypercholesterolemia patients on maximum statin therapy

**Reasoning Steps:**
1. Identified evidence tier: biomarker study measuring LDL cholesterol reduction over 12 weeks
2. Identified conclusion tier: company claims about cardiovascular protection, transforming outcomes for heart attack/stroke prevention
3. Assessed bridge: LDL reduction is a surrogate endpoint, not a direct measure of cardiovascular benefit
4. Noted absence of outcomes data and 4+ year timeline for actual cardiovascular evidence
5. Determined the leap from biomarker improvement to clinical benefit claims is unsupported by direct evidence

**Key Claims:**
- Company claims cardiovascular protection and improved heart attack/stroke outcomes based solely on LDL cholesterol reduction
- No direct cardiovascular outcomes evidence exists yet
- Accelerated approval sought based on surrogate endpoint alone

**Alternative Hypotheses:**
- Could be overclaim due to strong language like 'major breakthrough' and 'transform outcomes'
- Could be solid if focusing only on the LDL reduction finding itself

**Uncertainties:**
- Whether the 65% LDL reduction figure is statistically significant
- Exact wording of company claims vs. reporter interpretation
- Whether familial hypercholesterolemia context changes the evidence standard

**Self-Verification:**
- Confirmed this is biomarker evidence being used to support therapeutic outcome claims
- Verified no cardiovascular events were measured
- Double-checked that LDL reduction ≠ proven cardiovascular benefit
- Considered whether this could be solid - but the therapeutic benefit claims exceed the biomarker evidence

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 3.4/6 `#####.....`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 2.4/8 `###.......`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Sonnet** scored **37.0/100**.

**Best per dimension:**
- Correctness: Claude Sonnet (0.0/30)
- Support Strength: Claude Sonnet (0.0/8)
- Structural Reasoning: Claude Sonnet (4.8/8)
- Assumption Discipline: Claude Sonnet (3.4/6)
- Uncertainty Handling: Claude Sonnet (3.9/6)
- Alternative Hypothesis Quality: Claude Sonnet (4.5/6)
- Self Monitoring Quality: Claude Sonnet (2.4/8)
- Insight Depth: Claude Sonnet (8.0/8)
- Mechanism Quality: Claude Sonnet (0.0/10)
- Communication Efficiency: Claude Sonnet (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Sonnet | 11.2s | 37.0/100 | 3.3 |

Failure modes observed: missed_key_insight, unsupported_conclusion, unused_assumption, wrong_answer.
